$SLS
SELLAS Life Sciences Group, Inc.

2022 Q4 Form 10-Q Financial Statement

#000139047822000028 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $3.600M $2.864M
YoY Change 42.52% 17.57%
% of Gross Profit
Research & Development $5.846M $4.282M
YoY Change 72.3% -5.7%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.446M $7.146M
YoY Change 59.59% 2.42%
Operating Profit -$9.446M -$7.146M
YoY Change 59.59% 2.42%
Interest Expense $158.0K $111.0K
YoY Change 5450.0%
% of Operating Profit
Other Income/Expense, Net $167.0K $13.00K
YoY Change -96.51% -111.82%
Pretax Income -$9.121M -$7.022M
YoY Change 33.45% -0.89%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.121M -$7.022M
YoY Change 38.24% -0.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.34
Diluted Earnings Per Share -$0.44 -$0.34
COMMON SHARES
Basic Shares Outstanding 20.59M shares 20.55M shares
Diluted Shares Outstanding 20.56M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.13M $21.35M
YoY Change -19.81% -18.77%
Cash & Equivalents $17.13M $21.30M
Short-Term Investments
Other Short-Term Assets $631.0K $1.257M
YoY Change -62.64% -53.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.76M $22.61M
YoY Change -22.95% -21.98%
LONG-TERM ASSETS
Property, Plant & Equipment $874.0K $961.0K
YoY Change 20.89% 25.29%
Goodwill $1.900M $1.914M
YoY Change -0.73% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $399.0K $521.0K
YoY Change -32.83% -12.73%
Total Long-Term Assets $3.187M $3.396M
YoY Change -1.36% -62.17%
TOTAL ASSETS
Total Short-Term Assets $17.76M $22.61M
Total Long-Term Assets $3.187M $3.396M
Total Assets $20.94M $26.00M
YoY Change -20.29% -31.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.357M $2.127M
YoY Change 56.58% -16.42%
Accrued Expenses $6.286M $4.570M
YoY Change 138.11% 76.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.52M $12.55M
YoY Change 211.42% 136.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $577.0K $851.0K
YoY Change -39.01% -85.29%
Total Long-Term Liabilities $577.0K $851.0K
YoY Change -39.01% -85.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.52M $12.55M
Total Long-Term Liabilities $577.0K $851.0K
Total Liabilities $16.09M $13.40M
YoY Change 171.46% 18.15%
SHAREHOLDERS EQUITY
Retained Earnings -$179.9M -$170.8M
YoY Change 29.8% 29.39%
Common Stock $184.8M $183.4M
YoY Change 16.23% 15.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.851M $12.60M
YoY Change
Total Liabilities & Shareholders Equity $20.94M $26.00M
YoY Change -20.29% -31.49%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$9.121M -$7.022M
YoY Change 38.24% -0.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.152M -$5.746M
YoY Change 3.54% -2.25%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 929.0K 107.0K
YoY Change 1758.0% -95.23%
NET CHANGE
Cash From Operating Activities -5.152M -5.746M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 929.0K 107.0K
Net Change In Cash -4.223M -5.639M
YoY Change -14.27% 55.09%
FREE CASH FLOW
Cash From Operating Activities -$5.152M -$5.746M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$5.152M -$5.746M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001390478
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33958
dei Entity File Number
EntityFileNumber
001-33958
dei Entity Registrant Name
EntityRegistrantName
SELLAS Life Sciences Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8099512
dei Entity Address Address Line1
EntityAddressAddressLine1
7 Times Square, Suite 2503,
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
200-5278
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SLS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20588247 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21348000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21355000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1157000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1589000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
22605000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
23044000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
961000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
723000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
1914000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
1914000 usd
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
521000 usd
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
594000 usd
CY2022Q3 us-gaap Assets
Assets
26001000 usd
CY2021Q4 us-gaap Assets
Assets
26275000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2127000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2144000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4570000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2640000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
356000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
198000 usd
CY2022Q3 sls Acquired In Process Research And Development Payable Current
AcquiredInProcessResearchAndDevelopmentPayableCurrent
5500000 usd
CY2021Q4 sls Acquired In Process Research And Development Payable Current
AcquiredInProcessResearchAndDevelopmentPayableCurrent
0 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12553000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4982000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
680000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610000 usd
CY2022Q3 sls Fair Value Of Warrants Potentially Settleable In Cash
FairValueOfWarrantsPotentiallySettleableInCash
1000 usd
CY2021Q4 sls Fair Value Of Warrants Potentially Settleable In Cash
FairValueOfWarrantsPotentiallySettleableInCash
40000 usd
CY2022Q3 sls Contingent Purchase Price Consideration Net Of Current Portion
ContingentPurchasePriceConsiderationNetOfCurrentPortion
170000 usd
CY2021Q4 sls Contingent Purchase Price Consideration Net Of Current Portion
ContingentPurchasePriceConsiderationNetOfCurrentPortion
296000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
13404000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
5928000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20588247 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20588247 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15895637 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15895637 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
183378000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158948000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170783000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138603000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12597000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20347000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26001000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26275000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7600000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
200000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4282000 usd
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4541000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14422000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12281000 usd
CY2022Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10000000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2864000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2436000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8982000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3019000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8794000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
7146000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
6977000 usd
us-gaap Costs And Expenses
CostsAndExpenses
33504000 usd
us-gaap Costs And Expenses
CostsAndExpenses
21275000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7146000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6977000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-32504000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13675000 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2000 usd
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-30000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-39000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
29000 usd
CY2022Q3 sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
11000 usd
CY2021Q3 sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-140000 usd
sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
126000 usd
sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-403000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
111000 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
159000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
124000 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-108000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
324000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-426000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7022000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7085000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32180000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14101000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20562351 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20562351 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15874076 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15874076 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18932571 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18932571 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15344210 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15344210 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
19057000 usd
CY2022Q3 sls Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
69000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
455000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7022000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12597000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20347000 usd
sls Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
23065000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
85000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1280000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32180000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12597000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33415000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
275000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7085000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
26607000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27961000 usd
sls Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
9005000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
723000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14101000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
26607000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32180000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14101000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10000000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1280000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
723000 usd
sls Non Cash Lease Expense
NonCashLeaseExpense
334000 usd
sls Non Cash Lease Expense
NonCashLeaseExpense
0 usd
sls Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings
ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
39000 usd
sls Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings
ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
-29000 usd
sls Change In Fair Value Of Contingent Purchase Consideration
ChangeInFairValueOfContingentPurchaseConsideration
126000 usd
sls Change In Fair Value Of Contingent Purchase Consideration
ChangeInFairValueOfContingentPurchaseConsideration
-403000 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1128000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4500000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-505000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2181000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-17000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2112000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1930000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
666000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-344000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 usd
sls Increase Decrease In Contract With Customer Liability Net
IncreaseDecreaseInContractWithCustomerLiabilityNet
0 usd
sls Increase Decrease In Contract With Customer Liability Net
IncreaseDecreaseInContractWithCustomerLiabilityNet
-5600000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18657000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21045000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
sls Proceeds From Issuance Of Common Stock And Common Stock Warrants
ProceedsFromIssuanceOfCommonStockAndCommonStockWarrants
23065000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3019000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23150000 usd
CY2021Q3 sls Acquired In Process Research And Development Payable
AcquiredInProcessResearchAndDevelopmentPayable
0 usd
sls Proceeds From Issuance Of Common Stock And Common Stock Warrants
ProceedsFromIssuanceOfCommonStockAndCommonStockWarrants
9005000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
85000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12024000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9021000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21455000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35402000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21448000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26381000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
159000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
6000 usd
CY2022Q3 sls Acquired In Process Research And Development Payable
AcquiredInProcessResearchAndDevelopmentPayable
5500000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
449000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32200000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18700000 usd
sls Collaborative Arrangement Upfront Fee And Milestone Payments
CollaborativeArrangementUpfrontFeeAndMilestonePayments
10500000 usd
sls Proceeds From Research And Development Arrangement Milestone Payments
ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
13000000 usd
sls Research And Development Arrangement Potential Milestone Payments To Be Received
ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived
191500000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21300000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6516000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1294000 shares
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
667000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
217000 usd
CY2022Q3 sls Prepaid Research And Development
PrepaidResearchAndDevelopment
316000 usd
CY2021Q4 sls Prepaid Research And Development
PrepaidResearchAndDevelopment
1309000 usd
CY2022Q3 sls Prepaid Professional Services
PrepaidProfessionalServices
127000 usd
CY2021Q4 sls Prepaid Professional Services
PrepaidProfessionalServices
36000 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
47000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
27000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1157000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1589000 usd
CY2022Q3 sls Contract Research Payable
ContractResearchPayable
2947000 usd
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
300000 usd
CY2021Q4 sls Contract Research Payable
ContractResearchPayable
1325000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1228000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
989000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
203000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
165000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
192000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
161000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4570000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2640000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1395
sls Operating Lease Remaining Lease Term
OperatingLeaseRemainingLeaseTerm
P2Y3M
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
533000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1178000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
142000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1036000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
200000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
127000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
518000 usd
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5148000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1071000 shares
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7399000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
519000 shares
sls Class Of Warrant Or Right Grants
ClassOfWarrantOrRightGrants
4630000 shares
sls Classof Warrantor Right Canceled Or Expired
ClassofWarrantorRightCanceledOrExpired
1000 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5148000 shares
CY2020Q4 sls Research And Development Arrangement Potential Milestone Payments To Be Received Maximum
ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum
194500000 usd
CY2021Q4 sls Fair Value Of Warrants Liabilities
FairValueOfWarrantsLiabilities
40000 usd
sls Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
-39000 usd
CY2022Q3 sls Fair Value Of Warrants Liabilities
FairValueOfWarrantsLiabilities
1000 usd
CY2020Q4 sls Research And Development Arrangement Cash Payment Received
ResearchAndDevelopmentArrangementCashPaymentReceived
7500000 usd
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
9500000 usd
CY2020Q4 sls Research And Development Arrangement Cash Payment Received
ResearchAndDevelopmentArrangementCashPaymentReceived
7500000 usd
CY2020Q4 sls Research And Development Arrangement Milestones Probable Of Being Achieved
ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved
2000000 usd
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
9500000 usd
CY2021 sls Research And Development Arrangement Potential Milestone Payments To Be Received
ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived
192500000 usd
CY2022Q2 sls Proceeds From Research And Development Arrangement Milestone Payments
ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
1000000 usd
CY2022Q3 sls Research And Development Arrangement Potential Milestone Payments To Be Received
ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived
191500000 usd
CY2021Q3 sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
0 usd
CY2022Q3 sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
0 usd
sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
1000000 usd
sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
7600000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
200000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
455000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
275000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1280000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
723000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
534000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.09
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M7D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
681000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
543000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.28
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1071000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M23D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
282000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
18000 usd
CY2022Q3 sls Closing Price Of Common Stock
ClosingPriceOfCommonStock
2.02
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0300
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0101
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0195
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3857
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2463
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3154
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2129
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M4D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.78
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.99
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3400000 usd
sls Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition
EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition
P2Y8M19D

Files In Submission

Name View Source Status
0001390478-22-000028-index-headers.html Edgar Link pending
0001390478-22-000028-index.html Edgar Link pending
0001390478-22-000028.txt Edgar Link pending
0001390478-22-000028-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sls-20220930.htm Edgar Link pending
sls-20220930.xsd Edgar Link pending
sls-20220930ex311.htm Edgar Link pending
sls-20220930ex312.htm Edgar Link pending
sls-20220930ex321.htm Edgar Link pending
sls-20220930_g1.jpg Edgar Link pending
sls-20220930_cal.xml Edgar Link unprocessable
sls-20220930_def.xml Edgar Link unprocessable
sls-20220930_pre.xml Edgar Link unprocessable
sls-20220930_htm.xml Edgar Link completed
sls-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable